Lower risk of hospitalization (A) and death (B) is correlated with nirmatrelvir plus ritonavir treatment upon a positive SARS-CoV-2 test for patients with CLL. See supplemental Figure 2 in the article by Tadmor et al that begins on page 2239.
Lower risk of hospitalization (A) and death (B) is correlated with nirmatrelvir plus ritonavir treatment upon a positive SARS-CoV-2 test for patients with CLL. See supplemental Figure 2 in the article by Tadmor et al that begins on page 2239.
